Sofosbuvir-Velpatasvir (Epclusa®) – SMC approval

Following a resubmission, sofosbuvir-velpatasvir has been accepted for restricted use in NHS Scotland.

Sofosbuvir-velpatasvir was associated with high rates of sustained virologic suppression in adults with genotype 1 and 4 chronic HCV infection, including those with decompensated cirrhosis.

This Scottish Medicine Consortium (SMC) advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sofosbuvir-velpatasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

SMC has issued separate advice accepting the use of sofosbuvir-velpatasvir for the treatment of patients with genotype 3 (SMC No.1195/16) and for the treatment of patients with genotypes 2, 5 and 6 chronic HCV infection and for those patients with decompensated cirrhosis, irrespective of chronic HCV genotype (SMC No. 1271/17).